← Back to Search

Financial Incentives + NRT for Smoking Cessation

N/A
Recruiting
Research Sponsored by University of Vermont Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if financial incentives & medications help patients hospitalized for heart disease quit smoking. It could lead to better ways to get people to quit & improve health.

Who is the study for?
This trial is for adult smokers hospitalized due to a heart attack or heart surgery, living within 30 miles of UVMMC. Participants should be current cigarette users who have smoked more than 5 cigarettes per day in the past 3 months. Those with severe dementia, active cancer (except certain skin/prostate cancers), major exercise-limiting diseases, non-English speakers, or regular users of non-combusted tobacco are not eligible.
What is being tested?
The study is testing if financial rewards and nicotine replacement therapy can help cardiac patients quit smoking after being hospitalized for a serious heart event. The goal is to see if these methods increase adherence to quitting smoking compared to usual care without incentives.
What are the potential side effects?
Nicotine Replacement Therapy may cause mild side effects like nausea, headaches, skin irritation from patches, and sleep disturbances. Financial Incentives do not have direct medical side effects but could affect patient motivation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Biochemical verification of smoking status
Secondary study objectives
Cardiovascular Fitness
Other study objectives
Anxiety assessed by GAD-7 Questionnaire
Depression assessed by PHQ-9 questionnaire
Health Care Contacts
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention: Financial incentives and nicotine replacement therapy interventionExperimental Treatment1 Intervention
an intervention where patients are assigned to financial incentives and NRT of their choice; use of CO monitor to assess abstinence
Group II: Control: Usual CareActive Control1 Intervention
will receive standard treatment which entails referral to Vermont Quit Network. This network offers a wide range of free cessation services, including NRT and web-based modules on preparing to quit and developing a plan

Find a Location

Who is running the clinical trial?

University of Vermont Medical CenterLead Sponsor
42 Previous Clinical Trials
25,744 Total Patients Enrolled

Media Library

Intervention: Financial incentives and nicotine replacement therapy intervention Clinical Trial Eligibility Overview. Trial Name: NCT05738408 — N/A
Smoking Cessation Research Study Groups: Intervention: Financial incentives and nicotine replacement therapy intervention, Control: Usual Care
Smoking Cessation Clinical Trial 2023: Intervention: Financial incentives and nicotine replacement therapy intervention Highlights & Side Effects. Trial Name: NCT05738408 — N/A
Intervention: Financial incentives and nicotine replacement therapy intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05738408 — N/A
~15 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top